Drug Combo Proves Powerful Against Lung Cancer Roosevelt NY

A two-drug combination treatment in Roosevelt proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

Louis Juden Reed
(718) 863-8465
1180 Morris Park Ave
Bronx, NY
Farida P Chaudhri MD
(718) 358-3057
146-01 45th Ave
Flushing, NY
HOWARD HOFFMAN, MD
(718) 869-7636
327 Beach 19Th Street
Far Rockaway, NY
Irina Murakhovskaya, MD
1400 Pelham Pkwy S Ste 3N21
Bronx, NY
Rabindranath Bachan, MD
718-920-4826
111 E 210th St
Bronx, NY
Roopalekha Shenoy
(718) 518-5916
1650 Grand Concourse
Bronx, NY
Steven Edward Vogl
(718) 519-7774
2220 Tiemann Ave
Bronx, NY
YVETTE FRANCIS, MD
(718) 341-1991
23310 Linden Boulevard
Cambria Heights, NY
BARBARA SELIGMAN, MD
(718) 461-0446
14906 33Rd Avenue
Flushing, NY
Eva Grossman Radel, MD
718-920-7844
111 E 210th St
Bronx, NY
Data Provided by:
      

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Exercise for Breast Cancer Survival Roosevelt NY
Breast cancer is a physically and emotionally traumatizing disease. A study underrtaken at the Harvard School of Public Health examined four observational studies to determine whether physical activity could improve quality of life after a breast cancer diagnosis and on increased breast cancer survival.
- Exercise for Prostate Cancer Roosevelt NY
- Genetic Clues for Skin Cancer Therapies Roosevelt NY
- Fungal Infection Treatments Roosevelt NY
- Risks for Childhood Cancer Survivors Roosevelt NY
- Side Effect Of Chemotherapy Drugs Roosevelt NY
- Hormone Therapy for Breast Cancer Roosevelt NY
- Delayed Prostate Cancer Therapy Roosevelt NY
- Hormone Therapy for Lung Cancer Roosevelt NY